Moderna updates EUA timeline for pediatric COVID-19 vaccines
Moderna yesterday announced an updated timeline for its COVID-19 vaccine for children. According to Moderna, the Food and Drug Administration last week notified the drug maker that it may not complete its assessment of the company’s EUA request for children age 12 to 17 before January 2022. The delay is to evaluate recent international analyses of the risk of myocarditis after vaccination. As a result, Moderna said it will also delay requesting an EUA for its 50-microgram-dose version of the vaccine for 6- to 11-year-olds.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…